Huperzine A
improves
Cognition
Huperzine A
improves
Cognition
8.9
ValidityScore
Valid or Invalid?
Huperzine-A is a natural sesquiterpene alkaloid compound extracted from Huperzia Serrata (Chinese herb) which acts a reversible acetylcholinesterase (enzyme that break downs acetylcholine) inhibitor by crossing blood-brain barrier.
Huperzine-A has stronger penetration in blood brain barrier, prolonged duration of acetylcholinesterase inhibitory action and greater bioavailability than other cholinesterase inhibitors (donepezil, rivastigmine, and tacrine).
Huperzine-A has cognitive enhancing properties by protecting against several pathological factors inducing neurodegeneration such as beta-amyloid protein (or peptide), ischemia, hydrogen peroxide, glutamate, apoptosis and staurosporine-induced cytotoxicity. As a result, oxidative stress is reduced, expression of apoptotic proteins (Bcl-2, Bax, P53, caspase-3) gets regulated, protection of mitochondria and interference with amyloid precursor protein metabolism occurs, nerve growth factor and its receptors is up-regulated.
-
2019RCT
-
Bakht J, Gul A, Mehmood F -
«Patients with Alzheimer's Disease (AD) showed cognitive and task switching deficits in contrast with healthy individuals. There was significant improvement
in cognition and task switching abilities post Huperzine-A treatment compared with baseline performance.»
«One way ANOVA was conducted to see pre and post
Huperzine-A treatment differences on scores of ACE and
TMT with dementia severity (mild vs. moderate) as fixed
factor. Result showed that Huperzine-A treatment was equally
effective for mild and moderate dementia groups ACE F
(1,49) ¼ 1.27, p ¼ 0.26, mild (7.32 ± 3.77) moderate
(8.40 ± 2.92), TMT-A F (1,49) ¼ 0.26, p ¼ 0.61, mild
(91.28 ± 8.79) moderate (90.20 ± 5.88), TMT-B F.(1,49) ¼ 2.93, p ¼ 0.09, mild (119.76 ± 22.80) moderate
(130.76 ± 22.59)» - Dose: 0.2 mg twice a day
- Organism: Humans
- Notable Magnitude of Effect.
-
#10.1016/j.jcma.2018.07.004, 30839402, Aged, Alkaloids / therapeutic use*, Alzheimer Disease / drug therapy*, Alzheimer Disease / psychology, Amara Gul, Cholinesterase Inhibitors / therapeutic use*, Cognitive Dysfunction / drug therapy*, Double-Blind Method, Farah Mehmood, Female, Humans, Jehan Bakht, MEDLINE, Male, Middle Aged, NCBI, NIH, NLM, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, Neuropsychological Tests, PubMed Abstract, Sesquiterpenes / therapeutic use* -
-
2012RCT
-
Jiang XJ, Juan-Wu None, Liang XM, Xu ZQ, Zhang YF, Zhu CX -
«After 12 weeks of treatment, the MMSE, CDR, and ADL scores significantly improved in the Huperzine A group (P\0.01 for all
comparisons), whereas the placebo group did not show any
such improvement (P[0.05 for all comparisons). No
serious adverse events were recorded during the treatment.
Conclusion: Huperzine A can significantly improve the
cognitive function in patients with mild to moderate vascular dementia. Further, the medicament is safe» - Dose: 0.1-mg bid
- Organism: Humans
- Notable Magnitude of Effect.
-
Comments:
«The increase in MMSE score became statistically significant after 8 and 12 weeks of treatment (P < 0.01). By contrast, patients in control group did not show any such changes in MMSE scores (P > 0.05).»
«After 8 and 12 weeks of treatment, CDR scores in the treatment group decreased significantly (P < 0.01). By contrast, CDR scores in control group did not change significantly during the entire course of treatment (P > 0.05).»
«ADL score significantly decreased after 8 and 12 weeks of treatment with Huperzine A (P < 0.01). Furthermore, these changes were also significantly different compared to control group (P < 0.01). Patients in the control group did not demonstrate any significant change in ADL scores (P > 0.05) during the entire course of the treatment.» -
#10.1007/s12013-011-9258-5, 21833673, Activities of Daily Living, Aged, Alkaloids / pharmacology*, Alkaloids / therapeutic use*, Ascorbic Acid / therapeutic use, Cognition / drug effects*, Dementia, Double-Blind Method, Drug Administration Schedule, Female, Humans, MEDLINE, Male, Middle Aged, NCBI, NIH, NLM, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, Neuroprotective Agents / pharmacology*, Neuroprotective Agents / therapeutic use*, Placebo Effect, PubMed Abstract, Sesquiterpenes / pharmacology*, Sesquiterpenes / therapeutic use*, Severity of Illness Index, Vascular / drug therapy*, Xiao-Jiang Jiang, Xiao-Min Liang, Zhi-Qiang Xu -
-
2011RCT
-
B. Reynolds, C. Ward, For the Alzheimer's Disease Cooperative Study, J.T. Little, K. Behan, M.S. Rafii, P.S. Aisen, R. Thomas, S. Jin, S. Walsh -
«In the 400 mcg BID of huperzine A arm, the ADA-Cog change at week 16 demonstrated a 1.92 ± 5.30–point improvement (p = 0.07 for the LOCF ANCOVA), and at week 11, 400 μg BID dose showed a 2.27-point improvement vs a 0.29-point decline (p = 0.001 for the LOCF ANCOVA). The mixed-effects model of ADA-Cog change comparing the 400 mcg BID dose to placebo over 16 weeks showed a significant treatment group by time effect (p = 0.03), with greater cognitive improvement in the active treatment arm..»
- Organism: Humans
- Notable Magnitude of Effect.
-
#10.1345/aph.1L402, 19240260, Alicia R Desilets, Alkaloids, Alzheimer Disease / drug therapy*, Cholinesterase Inhibitors / therapeutic use*, Clinical Trials as Topic, Humans, Jennifer J Gickas, Kaelen C Dunican, MEDLINE, NCBI, NIH, NLM, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, Neuroprotective Agents / adverse effects, Neuroprotective Agents / therapeutic use*, PubMed Abstract, Sesquiterpenes / adverse effects, Sesquiterpenes / therapeutic use* -
ranked
added it
9 months ago
on May 22, 2020